Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Megalabs USA Announces Launch of Two New Products in North American Market: Abintra and Glutapak R
Wednesday, August 24, 2022Megalabs USA a subsidiary of Megalabs Inc that manufactures markets and distributes pharmaceutical products and nutritional supplements throughout the Americas has added two new products Abintra and Glutapak R to its North American portfolio These ad...
U.S. FDA Approves IMBRUVICA® (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease
Wednesday, August 24, 2022The Janssen Pharmaceutical Companies of Johnson Johnson announced today that the US Food and Drug Administration FDA has approved IMBRUVICA ibrutinib for the treatment of pediatric patients one year and older with chronic graftversushost disease cGV...
Can-Fite’s Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania
Tuesday, August 23, 2022CanFite BioPharma Ltd a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory cancer and liver diseases announced today its liver drug candidate Namodenoson has been approved for compassionate use fo...
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
Monday, August 22, 2022Pfizer Inc and BioNTech SE today announced they have completed a submission to the US Food and Drug Administration FDA requesting Emergency Use Authorization EUA of a booster dose of an Omicron BABAadapted bivalent COVID vaccine for individuals year...
Can-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31st European Academy of Dermatology and Venerology Congress
Monday, August 22, 2022CanFite BioPharma Ltd a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory cancer and liver diseases announced today that Dr Kim A Papp MD PhD will present latebreaking news at the st European Aca...
CG Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Ivaltinostat for the Treatment of Pancreatic Adenocarcinoma
Thursday, August 18, 2022CG Pharmaceuticals Inc announced the first patient dosed with the ivaltinostat and capecitabine combination therapy for the Phase b pancreatic adenocarcinoma PDAC maintenance study Commencement of treatment for the first patient began on Aug and th...
Valo Health Announces First Patient Dosed in the OPL-0401 Phase 2 study of an oral ROCK1/2 inhibitor for the Treatment of Non-Proliferative Diabetic Retinopathy
Thursday, August 18, 2022Valo Health Inc the technology company focused on transforming the drug discovery and development process using humancentric data and artificial intelligence today announced that dosing has commenced in its Phase study a multicenter randomized doub...
ProBioGen Executes a Master Service Agreement with NextPoint Therapeutics and Starts an Integrated Project from Cell Line Development to GMP Manufacturing
Wednesday, August 17, 2022ProBioGen is delighted to close a Master Service Agreement with NextPoint and initiate development and GMP manufacturing of their lead antibody candidate ProBioGens CHORiGHT cell line development including their latest DirectedLuck transposase and pl...
Tilray Medical Bolsters Market Leading Position in Europe With Market Authorization in Poland
Wednesday, August 17, 2022Tilray Brands Inc a leading global cannabislifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life today announced that its medical cannabis division Tilray Medical has received appr...
Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany
Tuesday, August 16, 2022Bristol Myers Squibb and Turning Point Therapeutics Inc today announced the expiration of the waiting period under the HartScottRodino Antitrust Improvements Act of as amended HSR Act and the receipt of merger control clearance from the Federal Cart...
